Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 19 of 38
Beyond Performance Status: Electronic Activity Monitoring to Assess Functional Activity of Patients With Gastrointestinal Malignancy During Chemotherapy.
NCT02909062
Validation of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)
NCT02836522
Developing a New Questionnaire About Patient Expectations of Breast Conserving Therapy
NCT02753673
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
NCT02737787
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
NCT02726399
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT02684253
Negative Pressure Wound Therapy in Post-Operative Incision Management
NCT02682316
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
NCT02697383
Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support
NCT02701829
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02657486
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
NCT02650752
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
NCT02650648
Single-agent Cobimetinib for Adults With Histiocytic Disorders
NCT02649972
Physician Use of Non-English Language Skills in Cancer Care
NCT02726360
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
NCT02633137
Electronic Reporting of Symptoms After Surgery
NCT02700256
A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
NCT02643498
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
NCT02642913
Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors
NCT02615054
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
NCT02609737
Body Composition and White Adipose Tissue Inflammation
NCT02713022
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
NCT02598752
Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
NCT02608619
Experience of Arab American Women With Breast Cancer: In-depth Interviews
NCT02710058
Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)
NCT02571673
Lung Cancer Exercise Training Study
NCT01068210
Emotion Regulation Therapy to Address Distress Among Caregivers
NCT02697357
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
NCT02572869
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
NCT02559115
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
NCT02563925
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
NCT02565017
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
NCT02553642
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
NCT02549989
Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
NCT02525653
Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors
NCT02519712
Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer
NCT02521363
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
NCT02496585
Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
NCT02494206
Caregiver Burden Within the Ambulatory Extended Recovery (AXR) Patient Population
NCT02501785
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
NCT02477202
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
NCT02450591
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
NCT02461550
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT02429375
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
NCT02422498
Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
NCT02437071
89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
NCT02410577
Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities
NCT02406274
Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion
NCT02376127
Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients
NCT02364726
Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy
NCT02356575
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.